AcquisitionOther

Day One Biopharmaceuticals, Inc. acquired Mersana Therapeutics, Inc.

Public deal record from 8-K. The source names the buyer and target, and terms are shown only when the filing or announcement discloses them.

Deal tape row

Day One Biopharmaceuticals, Inc. -> Mersana Therapeutics, Inc. · up to $55.25 per share (total deal value up to approximately $285 million)

Adding potential game-changing new medicine Emi-Le to portfolio to address underserved rare and life-threatening cancers in patients of all ages.